Copyright
©2013 Baishideng. All rights reserved.
World J Obstet Gynecol. May 10, 2013; 2(2): 21-33
Published online May 10, 2013. doi: 10.5317/wjog.v2.i2.21
Published online May 10, 2013. doi: 10.5317/wjog.v2.i2.21
Past, present and future of primary systemic treatment in breast cancer
José L Alonso-Romero, Antonio Piñero-Madrona, Department of Oncology and Surgery, “Virgen de la Arrixaca” University Hospital, 30120 Murcia, Spain
Author contributions: Alonso-Romero JL and Piñero-Madrona A contributed to the conception, design, writing and final approval.
Correspondence to: Antonio Piñero-Madrona, MD, PhD, Department of Surgery, “Virgen de la Arrixaca” University Hospital, Ctra Madrid-Cartagena s/n, 30120 Murcia, Spain. antonio.pinero@carm.es
Telephone: +34-968-369677 Fax: +34-968-395537
Received: January 27, 2013
Revised: February 12, 2013
Accepted: April 10, 2013
Published online: May 10, 2013
Processing time: 127 Days and 13.8 Hours
Revised: February 12, 2013
Accepted: April 10, 2013
Published online: May 10, 2013
Processing time: 127 Days and 13.8 Hours
Core Tip
Core tip: Primary systemic treatment is a fundamental part of breast cancer therapy, and it is applied to non-surgical and locally advanced tumours as well as surgical tumours to increase the likelihood of conservative treatment. As in any kind of tumour, an attempt should be made to include these patients in clinical trials to allow us to define the best and earliest individualised treatment strategy for our patients.